Skip to content
value.today

Hera Biotech, Inc.

Total raised
$2 M
1 round on record
Latest round
$2 M
Apr 2025
First round on record
Apr 2025
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Hera Biotech, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2025$2 MNo. 1Under $2 million

Hera Biotech, Inc.: Raise no. 1, Apr 2025

Investors in this round

26 investors had bought by the notice of Sep 23, 2026: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Somer Baburek · Executive Officer, Director
  • Neal Walsdorf, Jr. · Director
  • Paul Castella · Director
  • Teo Tijerina · Director
  • Wendy Smith · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds will be used to pay compensation to the execution officers named in response to Item 3 above.”

Signed by Somer Baburek, Ceo. Newest notice filed Sep 23, 2026. Read the notice at the SEC.

debt, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Hera Biotech, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2026).

    SEC Form D · Sep 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2026

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Hera Biotech, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Hera Biotech, Inc.
NameRoleNamed in
Somer BaburekExecutive officerSep 2026
Neal Walsdorf, Jr.DirectorSep 2026
Paul CastellaDirectorSep 2026
Somer BaburekDirectorSep 2026
Teo TijerinaDirectorSep 2026
Wendy SmithDirectorSep 2026